ABCL FY 2023 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena

ABCLAbCellera Biologics Inc.

$1B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$38M-92.2% YoY

Gross Profit

$38M100.0% margin

Operating Income

-$237M-623.8% margin

Net Income

-$146M-385.0% margin

EPS (Diluted)

$-0.51

Cash Flow

Operating Cash Flow

-$44M

Free Cash Flow

-$121M

Stock-Based Comp.

$64M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$336M

Stockholders' Equity

$1.2B

Cash & Equivalents

$133M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$38M	$485M	-92.2%
Gross Profit	$38M	$419M	-90.9%
Operating Income	-$237M	$217M	-209.6%
Net Income	-$146M	$159M	-192.4%